HardCardiologyHeart failure with reduced ejection fractionau-racpau-amc
A 68-year-old woman with ischaemic cardiomyopathy and left ventricular ejection fraction 30% is clinically euvolaemic on frusemide. She is not currently taking any disease-modifying heart failure medications. Her blood pressure is 118/72 mmHg and eGFR is 55 mL/min/1.73 m². According to Australian heart failure guidance, which combination of medications should be introduced as the foundational disease-modifying therapy?